| pubmed-article:16720236 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16720236 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:16720236 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:16720236 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:16720236 | lifeskim:mentions | umls-concept:C0041361 | lld:lifeskim |
| pubmed-article:16720236 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:16720236 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16720236 | pubmed:dateCreated | 2006-5-24 | lld:pubmed |
| pubmed-article:16720236 | pubmed:abstractText | Dendritic cells (DC) are professional antigen-presenting cells capable of inducing potent immune responses. In our ongoing clinical trials, human leukocyte antigen (HLA)-A2.1+ melanoma patients are vaccinated with mature DC, presenting tumor-derived peptides in major histocompatibility complexes (MHC) to naive T cells. Previously, we have shown that both intradermally and intranodally injected (111)In-labeled mature DC migrate to draining lymph nodes. However, little is known about the fate of the MHC-peptide complex after injection of these peptide-loaded DC. The aim of the present study was to develop radiolabeled, tumor-derived peptides to monitor their binding to MHC Class I. | lld:pubmed |
| pubmed-article:16720236 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16720236 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16720236 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16720236 | pubmed:month | May | lld:pubmed |
| pubmed-article:16720236 | pubmed:issn | 0969-8051 | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:AdemaGosse... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:FigdorCarl... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:OyenWim J GWJ | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:BoermanOtto... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:LavermanPeter... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:ScharenborgNi... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:de VriesI... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:BroekemaMatth... | lld:pubmed |
| pubmed-article:16720236 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:16720236 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16720236 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:16720236 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16720236 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16720236 | pubmed:pagination | 453-8 | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:meshHeading | pubmed-meshheading:16720236... | lld:pubmed |
| pubmed-article:16720236 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16720236 | pubmed:articleTitle | Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. | lld:pubmed |
| pubmed-article:16720236 | pubmed:affiliation | Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands. p.laverman@nucmed.umcn.nl | lld:pubmed |
| pubmed-article:16720236 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16720236 | lld:pubmed |
